Trial Profile
A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Capsaicin (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; Therapeutic Use
- Acronyms STRIDE
- Sponsors Astellas Pharma
- 28 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Dec 2010 New trial record